Issues
-
Cover Image
Cover Image
POT1 is a member of the shelterin complex, which binds telomeres and regulates their extension. Germline mutations in POT1 confer increased risk to a host of cancers, including glioma. Using native mouse models of glioma, it was found that deletion of POT had sex-specific effects on tumorigenesis, with females exhibiting decreased survival compared to males. Transcriptomic analysis and immunostaining validation studies revealed sex-specific changes in immune populations, with females exhibiting decreased expression of microglia/macrophage markers. Artwork by Emma Vidal. For details, see article by Jalali and colleagues on page 2703. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Review
Cancer Research Highlights
Genome and Epigenome
Genome-Wide DNA Methylation Profiling of Esophageal Squamous Cell Carcinoma from Global High-Incidence Regions Identifies Crucial Genes and Potential Cancer Markers
Metabolism and Chemical Biology
Molecular Cell Biology
MYC-Activated LncRNA MNX1-AS1 Promotes the Progression of Colorectal Cancer by Stabilizing YB1
YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells
Tumor Biology and Immunology
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy
Porphyromonas gingivalis Promotes Colorectal Carcinoma by Activating the Hematopoietic NLRP3 Inflammasome
Translational Science
The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy
Population and Prevention Science
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.